EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Interleukin 33 Promotes Liver Sinusoidal Endothelial Cell Dysfunction and Hepatic Fibrosis in Diabetic Mice

Huimin Chen, Chao Gao, Li Mo, Xingzhu Yin, Li Chen, Bangfu Wu, Ying Zhao, Xueer Cheng, Chanhua Liang, Bichao Xu, Dongyan Li, Yanyan Li und 2 weitere

Diabetes & Metabolism Journal · 01.11.2025 · 49 (6) · 1204-1218

DOI: 10.4093/dmj.2024.0532 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes & Metabolism Journal, erschienen am 01.11.2025. Verfasst von Huimin Chen und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nutrition and Food Hygiene, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Chin…. Hauptthemen laut MEDLINE: Interleukin-33, Liver Cirrhosis, Endothelial Cells, Diabetes Mellitus, Experimental. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Applied Basic Frontier Special Project of Wuhan Science and Technology Bureau, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Interleukin 33 (IL33) drives liver fibrosis, and individuals with type 2 diabetes mellitus are more likely advanced to liver fibrosis. However, the role of IL33 in diabetic liver fibrosis remains unclear, prompting our investigation.

Methods

We developed a diabetes model in wild-type, IL33−/−, and suppression of tumorigenicity 2 (ST2−/−, IL33 receptor) mice. Furthermore, wild-type diabetic mice were injected with IL33 neutralizing antibody (αIL33). We also co-cultured human liver endothelial cells and human hepatic stellate cells to identify the role of IL33 in high palmitic acid and high glucose conditions.

Results

Hepatic collagen deposition was increased in diabetic mice, which was alleviated by IL33 knockout, ST2 knockout, or administration of αIL33. Also, αIL33 treatment blunted liver sinusoidal endothelial cell (LSEC) dysfunction and inflammation during diabetic liver fibrosis progression. Recombinant IL33 (rIL33) treatment aggravated autophagy disruption in the presence of palm acid and high glucose in LSECs, which was blunted by autophagy agonist rapamycin administration and ERK/MAPK inhibitor PD98059 treatment. Hepatic stellate cell line LX-2 co-cultured with rIL33-pretreated LSECs displayed augmented activation, which was also attenuated by rapamycin or PD98059 pretreated.

Conclusion

IL33 drives LSEC dysfunction and promotes diabetic hepatic fibrosis, thus a potential therapeutic target for diabetic liver fibrosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-33Liver CirrhosisEndothelial CellsDiabetes Mellitus, ExperimentalLiverDiabetes Mellitus, Type 2AnimalsMiceHumansMice, KnockoutMaleHepatic Stellate CellsMice, Inbred C57BL

Stichwörter der Autor:innen

AutophagyDiabetes mellitusEndothelial cellsInterleukin-33Liver cirrhosis

Substanzen

Interleukin-33Il33 protein, mouse

Autor:innen und Institutionen

  • Department of Nutrition and Food Hygiene, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • National Institute for Nutrition and Health, Chinese Center for Disease Control and Prevention, Beijing, China.
  • Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China.
  • Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Shenzhen Center for Chronic Disease Control, Shenzhen, China.
  • Hubei Key Laboratory of Food Nutrition and Safety, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Förderung

  • Applied Basic Frontier Special Project of Wuhan Science and Technology Bureau
  • National Natural Science Foundation of China

Zitieren

APA

Chen, H., Gao, C., Mo, L., Yin, X., Chen, L., Wu, B., Zhao, Y., Cheng, X., Liang, C., Xu, B., Li, D., Li, Y., Yao, P., & Tang, Y. (2025). Interleukin 33 Promotes Liver Sinusoidal Endothelial Cell Dysfunction and Hepatic Fibrosis in Diabetic Mice. Diabetes & Metabolism Journal, 49(6), 1204-1218. https://doi.org/10.4093/dmj.2024.0532

Vancouver

Chen H, Gao C, Mo L, Yin X, Chen L, Wu B, et al. Interleukin 33 Promotes Liver Sinusoidal Endothelial Cell Dysfunction and Hepatic Fibrosis in Diabetic Mice. Diabetes & Metabolism Journal. 2025;49(6):1204-1218. doi:10.4093/dmj.2024.0532

BibTeX
@article{Chen2025,
  author = {Chen, Huimin and Gao, Chao and Mo, Li and Yin, Xingzhu and Chen, Li and Wu, Bangfu and Zhao, Ying and Cheng, Xueer and Liang, Chanhua and Xu, Bichao and Li, Dongyan and Li, Yanyan and Yao, Ping and Tang, Yuhan},
  title = {Interleukin 33 Promotes Liver Sinusoidal Endothelial Cell Dysfunction and Hepatic Fibrosis in Diabetic Mice},
  journal = {Diabetes & Metabolism Journal},
  year = {2025},
  volume = {49},
  number = {6},
  pages = {1204--1218},
  doi = {10.4093/dmj.2024.0532}
}
Kostenlos starten →